1. Norway Stocks

  2. •

    Health technology

  3. •

    Medical specialties
ArcticZymes Technologies ASA

ArcticZymes Technologies ASA

19.85
NOK
-0.35
(-1.73%)
0.29EPS
68.71P/E
1.03BMarket Cap
Nov 05Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.58
0.78
1.21
1.62
1.52
1.45
0.93
1.93
2.59
2.72
2.35
2.05
2.21
2.31
Basic EPS, GAAP
-0.6
-0.51
-0.4
-0.47
-0.57
-0.31
-0.13
1.72
0.94
0.65
0.38
0.17
0.19
0.29
Free Cash Flow per Basic Share
-0.5
-0.54
-0.33
-0.47
-0.62
-0.39
0.06
0.93
1.28
0.91
0.1
-0.15
0.43
0.43
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.06
2.26
1.96
1.54
0.98
1.07
0.93
4.02
4.86
5.63
6.08
6.35
6.62
6.79
Tangible Book Value per Share
0.92
2.14
1.85
1.41
0.81
0.91
0.92
4.01
4.83
5.45
5.57
5.7
5.96
6.15
Basic Weighted Avg Shares
38
42
44
44
44
46
48
48
49
50
51
51
51
55
Sales/Revenue/Turnover
22
33
53
71
67
67
45
93
128
137
119
104
113
126
Operating Margin (%)
-109.35
-73.97
-34.7
-29.41
-37.36
-20.23
-0.91
45.79
45.66
26.63
13.24
-1.38
2.33
9.17
Depreciation Expense
2
2
3
2
2
5
5
10
3
5
6
7
9
9
Net Income, GAAP
-23
-22
-17
-20
-25
-14
-6
83
46
33
19
8
10
16
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
21.39
22.03
21.56
19.96
18.84
17.28
Profit Margin (%)
-103.53
-65.21
-32.55
-28.77
-37.4
-21.26
-14.13
88.95
36.24
23.99
16.33
8.12
8.65
12.67
Working Capital
31
88
78
59
30
39
33
159
209
245
258
269
289
295
LT Debt
- -
- -
- -
- -
17
15
13
10
14
10
8
4
4
15
Total Equity
43
99
87
68
44
52
46
196
245
285
309
324
338
347
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
19.52
10.13
3.98
-0.35
0.63
2.74
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
19.94
11.9
6.38
2.67
2.95
4.58
Return on Common Equity (%)
-73.35
-30.74
-18.78
-26.64
-45.18
-30.05
-13.2
69.41
21.12
12.41
6.54
2.67
2.94
4.75

Capital Structure

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
4
15
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
1,052
996
1,027

Working Capital

NOK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
308
308
313
Cash, Cash Equivalents & STI
263
264
269
Accounts Receivable, Net
22
20
19
Inventories
16
15
15
Total Current Liabilities
19
19
18
Payables & Accruals
- -
- -
- -
ST Debt
1
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

NOK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
33.27%
11.76%
4.34%
Free Cash Flow
68.13%
-141.51%
-381.84%
Net Income, GAAP
-161.55%
-31.13%
14.97%
Sales/Revenue/Turnover
12.83%
5.29%
7.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
30
27
23
25
104
2025
23
27
29
34
113
2026
32
32
- -
- -
- -

Quarterly Earnings Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.05
-0.03
0.06
0.17
2025
-0.06
0.06
0.06
0.13
0.19
2026
0.01
0.1
- -
- -
- -

Quarterly Dividends Per Share

NOK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Michael B. Akoh
Full Time Employees
51
Sector
Health technology
Industry
Medical specialties
Address
Sykehusveien 23 Tromsø TR Norway 9294
IPO Date
Nov 8, 2005
Website
arcticzymes.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
ArcticZymes Technologies ASA develops, manufactures, and commercializes recombinant enzymes for molecular research, in vitro diagnostics, and biomanufacturing applications, including salt-active nucleases that perform effectively in high-salt and low-temperature conditions. The company offers core products such as M-SAN HQ and SAN HQ nucleases for DNA and chromatin removal in viral vector production for gene therapy and vaccines; GMP-grade variants including M-SAN HQ GMP, SAN HQ GMP, and SAN HQ GMP neo; ELISA kits like SAN HQ ELISA SensoPlus for residual enzyme detection; molecular tools including Cod Uracil-DNA Glycosylase, T7 RNA Polymerase, AZtaq DNA Polymerase, R2D Ligase, and Proteinase HQ; and supporting enzymes for PCR, RNA manipulation, and bioprocessing workflows. Founded in 1990 and headquartered in Tromso, Norway, ArcticZymes Technologies operates globally with primary revenue from the USA, Europe, and other regions, serving biopharmaceutical manufacturers, research institutions, and diagnostic developers through its ArcticZymes AS subsidiary. Recent developments include the launch of GMP-grade M-SAN HQ in 2025 to enhance viral vector manufacturing integration; introduction of SAN HQ ELISA SensoPlus and SAN HQ GMP neo in December 2024 for cell, gene, and vaccine biomanufacturing; an exclusive European distribution partnership with Brenntag Specialists Pharma in 2025 for its bioprocess nuclease range; extension of research collaboration with the Austrian Centre of Industrial Biotechnology on salt-active nucleases for bionanoparticle purification; and a new board chairman appointment in 2024 alongside strategic hires in business development and marketing to drive customer-centric growth.